Targeting Prolyl Hydroxylase to Overcome Iron Deficiency and Inflammation-Related Anemia in Rats: A Novel Therapeutic Approach
In healthy rats, JNJ-42905343 increased the expression of genes related to iron absorption and plasma EPO levels. Over 28 days, it elevated hemoglobin, MCH, and MCV, and showed a dose-dependent effect on serum iron levels. In the inflammation model, JNJ-42905343 corrected anemia and FID by increasing hemoglobin, MCH, and MCV, and it was found to work through increasing the expression of genes that enhance iron availability in the duodenum. In contrast, rhEPO did not affect these genes and was ineffective in the inflammation model.
The research concludes that PHD inhibition positively impacts iron metabolism and EPO release, suggesting that PHD inhibitors like JNJ-42905343 offer a unique therapeutic approach for anemia and FID, distinct from rhEPO.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.
Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.
By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.
Click on the image below to go directly to the Translational Medicine search interface.
